

# Development of an ultra-sensitive assay for anti-sense oligonucleotide quantification

Featuring the SCIEX Triple Quad™ 7500 LC-MS/MS System – QTRAP<sup>®</sup> Ready, powered by SCIEX OS Software

# Ji Jiang, Eshani Nandita, Lei Xiong SCIEX, USA

A notable 4-fold improvement in S/N was achieved for the quantification of an anti-sense oligonucleotide (ASO) when comparing the new SCIEX 7500 System with the previous generation of instrumentation (Figure 1). This new level in sensitivity for challenging analytes in matrix opens doors for accurate bioanalysis and metabolism studies with excellent specificity not achievable with orthogonal methods.

Oligonucleotide therapeutics and gene therapies are rapidly gaining attention as their potency improves and delivery challenges are addressed. Modalities such as ASOs are becoming more important due to their high specificity and capability for treating formerly undruggable targets. Recently, an increase in the number of candidates entering clinical trials and approvals have been observed, triggering increased demand for highly sensitive and robust quantitative bioanalytical methods to understand their pharmacokinetic profiles and metabolism. Conventional approaches for oligonucleotide bioanalysis involve ligand-binding assays (LBA) and fluorescence-based detection primarily due to achieving low detection limits. While such techniques can be highly sensitive, there are limitations in coverage of the linear dynamic range (LDR). Moreover, both assays lack specificity in distinguishing oligonucleotide products from related impurities and metabolites. Furthermore, assays



**Figure 1. Sensitivity gains for ASO in human plasma.** Representative XICs at 0.5 ng/mL are displayed for both systems showing a notable 4-fold increase in sensitivity and S/N.

utilizing fluorescence-based detection often suffer from low throughput due to extensive run times. Orthogonal technologies such as mass spectrometry (MS) have been routinely employed for bioanalytical studies of oligonucleotides since the platform is capable of both differentiating between target oligonucleotides and associated components: and providing high-throughput capabilities. However, the extent of MS use to date has been limited by its ability to quantify the ultra-low analyte levels in complex biological matrices.

Herein, ASO in extracted human plasma was quantified using liquid chromatography (LC) coupled to a SCIEX 7500 System. The sensitivity of the assay was significantly enhanced over previous generations of instrumentation by multiple hardware improvements on the ion source and the front end of the mass analyzer. The analyte was quantified at 0.2 ng/mL with outstanding reproducibility, accuracy, and linearity, proving the robustness and performance of the developed method. With this method an LC-MS assay addresses what was previously only achievable with LBAs and fluorescence detection, while offering the potential to simultaneously monitor closely related impurities and/or metabolites.

# Key features of anti-sense oligonucleotide quantification using SCIEX 7500 System

- 4-fold S/N improvement was observed compared to the SCIEX QTRAP 6500+ System (Figure 1)
- Lowest limit of quantification (LLOQ) of 0.2 ng/mL was achieved for ASO in human plasma
- Greater ion generation and ion transmission enabling significant gains in sensitivity due to hardware improvements on the SCIEX 7500 System such as the OptiFlow<sup>®</sup> Pro Ion Source with E Lens<sup>™</sup> Technology and the D Jet<sup>™</sup> Ion Guide<sup>1</sup>
- A user-friendly interface providing a single, compliance-ready platform for data acquisition, flexible processing, and management within SCIEX OS Software



## Methods

Samples and reagents: All reagents, including 1,1,1,3,3,3hexafluoro isopropanol (HFIP)≥ 99.8%, diisopropylethylamine (DIEA) 99.5 % and ethylenediaminetetraacetic acid (EDTA) were purchased from Sigma Aldrich. The customized oligonucleotide standards were synthesized by Integrated DNA Technologies (IDT), including the 20mer analyte of a fully phosphorothioated (\*) and 2'O-methylated RNA (m) ASO

(mU\*mA\*mU\*mC\*mC\*mG\*mC\*mC\*mU\*mC\*mG\*mU\*mG\*mA\*m G\*mA\*mA\*mG\*mA\*mU), the 21mer internal standard (IS) of a fully phosphorothioated ASO

(G\*C\*G\*T\*T\*T\*G\*C\*T\*C\*T\*T\*C\*T\*T\*C\*T\*T\*G\*C\*G), and a carrier oligonucleotide to minimize non-specific binding (CATGGTCCTGCTGGAAGTTCGTG). The Clarity OTX solid phase extraction (SPE) kit was obtained from Phenomenex. Human plasma was purchased from BioIVT.

**Sample preparation:** 100  $\mu$ L of human plasma mixed with 100  $\mu$ L of lysis loading buffer (Clarity OTX kit) was extracted using the Clarity OTX SPE plate following the manufacturer's protocol. In short, the SPE plate was activated with 1 mL methanol and equilibrated with 1 mL equilibration buffer. After equilibration, human plasma mixed with lysis-loading buffer was loaded onto the plate and washed with 1 mL washing buffer for a total of 3 times and subsequently eluted with 1 mL elution buffer. The eluted samples were dried down with N<sub>2</sub> gas at 40 °C and reconstituted in 100  $\mu$ L mobile phase A (100 mM HFIP and 15 mM DIEA in water) containing 100  $\mu$ M EDTA. The calibration curve ranging from 0.05 ng/mL to 10,000 ng/mL was prepared by spiking the analyte ASO into extracted human plasma along with 1  $\mu$ g/mL IS and 2  $\mu$ g/mL carrier oligonucleotide.

**Chromatography:** A gradient profile was used at a flow rate of 300 µL/min (Table 1) using an ExionLC<sup>TM</sup> system equipped with a Waters Acquity BEH C18 column (2.1×50 mm, 1.7 µm, 130Å). The mobile phase A consisted of water with 15 mM DIEA and 100 mM HFIP, while the organic phase B was 15 mM DIEA and 100 mM HFIP in 90 % methanol (*v*:*v*). The column oven

#### Table 1. LC conditions.

Time	Mobile phase A (%)	Mobile phase B (%)
0	85	15
3.0	65	35
3.1	2.0	98
4.5	2.0	98
4.6	85	15
6.0	85	15

temperature was set to 60°C. The injection volume was 20  $\mu L$  for each system.

*Mass spectrometry:* On-column method development was performed, as transitions and source/gas parameters are highly dependent on LC-MS conditions. In order to compare the sensitivity difference between the SCIEX QTRAP 6500+ System and SCIEX 7500 System, the calibration curve samples were injected and analyzed in triplicates on both systems with the same MS-dependent parameters, but adjusted source/gas parameters for each instrument. Tables 2-3 summarize the MS parameters that were optimized for each specific hardware configuration.

#### Table 2. MS parameters.

Parameter	SCIEX 6500+ QTRAP System	SCIEX 7500 System	
lon source gas	70 psi	80 psi	
lon source gas	70 psi	90 psi	
Curtain gas	35 psi	40 psi	
lon spray voltage	-4500 V	-3500 V	
Source temperature	400 °C	350 °C	
Declustering potential	-80 V	NA	
CAD gas	High	14	

Table 3. MRM parameters. MRM specifications were the same on both the SCIEX 6500+ and SCIEX 7500 Systems.

ID	Q1	Q3	CE	СХР	EP
20mer ASO	694.2	374.0	-37 V	-10 V	-10 V
IS	741.4	319.0	-35 V	-12 V	-10 V

**Data processing:** MRM data were processed by using SCIEX OS Software 2.0. The MQ4 algorithm was used for peak integration.



### **Quantification results**

Investigation of improvements in sensitivity were performed using the same ASO calibration set on the SCIEX QTRAP 6500+ System and the SCIEX 7500 System.

With novel hardware improvements, the presented LC-MRM assay demonstrated ultra-high sensitivity for quantification of ASO in human plasma with the LLOQ at 0.2 ng/mL and LOD at 0.05 ng/mL (Figure 2). On the SCIEX QTRAP 6500+ System, a concentration of 0.2 ng/mL was detectable. Using the SCIEX 7500 System, this level can now be solidly quantified with %CV below 6% for all tested samples (Figure 3). Overall, the SCIEX 7500 System offers a notable 4-fold enhancement in S/N.

Both systems offer an LDR covering 4.5 orders of magnitude (Figure 3 and Figure 4). However, a lower LLOQ is enabled with the SCIEX 7500 System for ASO quantification in matrix with great accuracy and reproducibility for the entire range of concentrations (Figure 3). Therefore, the LC-MRM method provides substantial improvement in monitoring low-level analytes when compared with LBAs and fluorescence-based detection.

SCIEX 7500 System provides innovative hardware designs that facilitate greater ion generation and ion sampling. Improvements feature the OptiFlow Pro Ion Source with E Lens Technology which increases ion generation and the D Jet Ion Guide which enables higher efficient capture and transmission of analyte ions

behind the orifice plate.<sup>1</sup> These highlighted features contributed to the observed increase in sensitivity and S/N compared to previous instrument generations.



Figure 2. A LLOQ of 0.2 ng/mL and LOD of 0.05 ng/mL was achieved on the SCIEX 7500 System. Representative XICs at 0.05, 0.2, 0.5, and 1 ng/mL are displayed indicating improvements in LOD and LLOQ.



Calibration for Methy-Oligo: y = 14967.70140 x + -391.07327 (r = 0.99974, r<sup>2</sup> = 0.99949) (weighting: 1 / x)



		Concentration						
	Row	Component Name	Actual Concentration	Num. Values	Mean	Standard Deviation	Percent CV	Accuracy
	1	Methy-Oligo	0.05	3 of 3	5.985e-2	5.160e-4	0.86	119.70
	2	Methy-Oligo	0.10	3 of 3	9.557e-2	7.864e-3	8.23	95.57
	3	Methy-Oligo	0.20	3 of 3	1.955e-1	2.905e-3	1.49	97.73
	4	Methy-Oligo	0.50	3 of 3	4.355e-1	2.782e-2	6.39	87.10
	5	Methy-Oligo	1.00	3 of 3	8.031e-1	3.434e-2	4.28	80.31
•	6	Methy-Oligo	2.00	3 of 3	2.011e0	9.112e-2	4.53	100.53
	7	Methy-Oligo	5.00	3 of 3	5.224e0	1.030e-1	1.97	104.49
	8	Methy-Oligo	10.00	3 of 3	1.053e1	1.473e-1	1.40	105.30
	9	Methy-Oligo	50.00	3 of 3	5.217e1	2.121e-1	0.41	104.34
	10	Methy-Oligo	100.00	3 of 3	1.049e2	1.032e0	0.98	104.91
	11	Methy-Oligo	500.00	3 of 3	5.076e2	2.746e0	0.54	101.52
	12	Methy-Oligo	1000.00	3 of 3	9.848e2	9.007e0	0.91	98.48

Figure 3. Quantification results for ASO in human plasma from SCIEX 7500 System. Calibration curve of ASO in human plasma with an LDR covering 0.05 ng/mL to 1,000 ng/mL (top). Exceptional %CV and accuracy results demonstrated the overall robustness and performance of the LC-MRM assay (bottom).



	Concentration							
	Row	Component Name	Actual Concentration	Num. Values	Mean	Standard Deviation	Percent CV	Accuracy
►	1	methy-oligo	0.50	3 of 3	5.117e-1	6.056e-2	11.83	102.35
	2	methy-oligo	1.00	3 of 3	8.579e-1	1.138e-1	13.27	85.79
	3	methy-oligo	2.00	3 of 3	2.038e0	4.439e-2	2.18	101.92
	4	methy-oligo	5.00	3 of 3	4.832e0	5.703e-2	1.18	96.64
	5	methy-oligo	10.00	3 of 3	9.554e0	1.640e-1	1.72	95.54
	6	methy-oligo	50.00	3 of 3	4.854e1	4.842e-1	1.00	97.08
	7	methy-oligo	100.00	3 of 3	1.015e2	2.476e0	2.44	101.54
	8	methy-oligo	500.00	3 of 3	5.427e2	3.468e1	6.39	108.53
	9	methy-oligo	1000.00	3 of 3	1.122e3	2.964e1	2.64	112.24
	10	methy-oligo	10000.00	3 of 3	9.836e3	2.501e2	2.54	98.36

Figure 4. Quantification results for ASO in human plasma from SCIEX QTRAP 6500+ System. Calibration curve with an LDR covering 0.5 ng/mL to 10,000 ng/mL (top). %CV and accuracy results proved method reproducibility and accuracy (bottom).



# Conclusions

- An ultra-sensitive LC-MRM method for quantifying a highly modified ASO was demonstrated with a 4-fold enhancement in S/N compared to previous instrument generations
- Unprecedented sensitivity for ASO quantification with an LLOQ at 0.2 ng/mL in matrix was achieved with the SCIEX 7500 System
- Exceptional accuracy and reproducibility with an LDR of 4.5 orders of magnitude was obtained
- High throughput needs are addressed with a method run time of 6 min
- The high specificity of the presented LC-MS assay allows for simultaneous quantification of multiple closely related species which cannot be achieved with orthogonal assays

### References

1. Enabling new levels of quantification. <u>SCIEX technical note</u> <u>RUO-MKT-02-11886-A</u>.

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to https://sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries.

© 2020 DH Tech. Dev. Pte. Ltd. RUO-MKT-02-12551-B. AB SCIEX™ is being used under license.



Headquarters 500 Old Connecticut Path | Framingham, MA 01701 USA Phone 508-383-7700 sciex.com

International Sales For our office locations please call the division headquarters or refer to our website at sciex.com/offices